Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

The vast majority of acute heart failure episodes are characterized by increasing symptoms
and signs of congestion with volume overload. The goal of therapy in those patients is the …

Aims Inhibition of sodium–glucose co‐transporter 2 (SGLT2) reduces the risk of death and
heart failure (HF) admissions in patients with chronic HF. However, safety and clinical …

Aims Effective and safe decongestion remains a major goal for optimal management of
patients with acute heart failure (AHF). The effects of the sodium–glucose cotransporter 2 …

Acute heart failure (AHF) is a syndrome defined as the new onset (de novo heart failure
(HF)) or worsening (acutely decompensated heart failure (ADHF)) of symptoms and signs of …

Congestion is the main reason for hospitalization in patients with acute decompensated
heart failure and is an important target for therapy. However, achieving complete …

Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of …

Aims Classification of acute heart failure (AHF) patients into four clinical profiles defined by
evidence of congestion and perfusion is advocated by the 2016 European Society of …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors improve clinical outcome in
patients with heart failure (HF), but the mechanisms behind their beneficial effects are not yet …

ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …